Treat-and-resect Study of Echo Decorrelation Imaging-controlled Radiofrequency Ablation in Liver Tumors
Key facts
- Who runs it
- University of Cincinnati
- Where
- Cincinnati, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Started
- 11 Jul 2022
- Ended
- 15 Jan 2024
- Type of study
- Interventional, 2 groups
- Treatments tested
- RFA controlled using echo decorrelation imaging
- RFA controlled using standard manufacturer-specified algorithms
- Record updated
- 29 August 2024
- Why it stopped
- Lack of resources to execute study.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Age ≥18 years
- Scheduled for resection of at least one confirmed primary or metastatic liver tumor with estimated diameter <5 cm at the University of Cincinnati Medical Center (UCMC)
- Patients may have other disease (typically cirrhosis, hepatitis B or hepatitis C) for primary liver cancer patients and extrahepatic cancer (typically colorectal) for metastatic liver cancer patients
- Ability to understand and the willingness to sign the written research informed consent document for this study
Who cannot take part
- The tumor for which the resection is scheduled is greater than or equal to 5 cm in diameter
- The tumor for which the resection is scheduled has received: prior ablation; chemoembolization; or, other treatment which in the opinion of the PI would disqualify a patient from participation
- Patients who are receiving any other investigational agents. Patients who have received other investigational agents previously who are no longer receiving these investigational agents may be eligible at the discretion of the PI
- Radiofrequency ablation (RFA) is contra-indicated for safety reasons in the opinion of the PI and/or clinical treatment team according to current standards of care (e.g., tumor adjacent to the heart, bowel, gall bladder, or bile ducts; impaired liver function; implanted cardiac devices)
- Proceduralist assessment that research-specific radiofrequency ablation or intraoperative ultrasound imaging would cause substantial patient risk
- Pregnant women, prisoners, institutionalized individuals, or other individuals from vulnerable populations
Where in United States
- University of Cincinnati Medical CenterCincinnati, United States
About the trial
What the trial wants to find out
This study will comprise the first pilot clinical trial of 3D, ultrasound-based thermal ablation control using echo decorrelation imaging, directly testing the capability of this approach to ensure reliable tumor treatment. The purpose of this study is to determine the ability of ultrasound echo decorrelation to successfully predict complete ablation of human hepatocellular carcinoma, concomitant diseased liver, and metastatic liver cancer and to determine the potential of echo decorrelation imaging to provide effective real-time control of radiofrequency ablation (RFA) in liver tumors.
The 2 groups in the trial
- arm 1: generator-controlled RFATreatment being tested
In up to 6 patients (arm 1: generator-controlled RFA), RFA will be performed directly following manufacturer-specified algorithms, with recording of 3D ultrasound echo decorrelation images during ablation.
Treatment: RFA controlled using standard manufacturer-specified algorithms
- arm 2: imaging-controlled RFATreatment being tested
In up to 6 additional patients (arm 2: imaging-controlled RFA), real-time, 3D echo decorrelation imaging during ablation will provide an additional treatment end point.
Treatment: RFA controlled using echo decorrelation imaging
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 29 August 2024